Connectyx Technologies Holdings Group has signed a marketing agreement with the Hereditary Neuropathy Foundation (HNF). The agreement is expected to allow Connectyx to promote its MedFlash Personal Health manager directly to HNF's membership and their families.

HNF promotes and supports both clinical and primary Charcot-Marie Tooth disease (CMT) research.

While HNF members give a face to CMT, the foundation provides an organisational voice to those living with CMT all over the world. HNF continues to educate physicians, along with the entire medical community, about CMT.

Allison Moore, founder and president of HNF, said: “HNF is thrilled to become a strategic partner of MedFlash. It is critical that CMT patients carry with them at all times a list of neurotoxic drugs to avoid potentially debilitating or even lethal side effects from contraindicated drug treatments.

“Furthermore, when dealing with a genetic neurological disease like CMT, family history is critical to diagnosis and treatment. It can not only prevent medical catastrophes but also reduce unnecessary testing to obtain a diagnosis. “

Ronn Schuman, president and CEO of Connectyx Technologies, said: “The MedFlash Personal Health Manager will be a valuable tool for their members.”

HNF is a non-profit organisation that focuses on raising awareness, funding scientific research, and educating the medical community as well as the general public about Charcot-Marie Tooth disease (CMT). HNF offers people with CMT, and their families, medical information and emotional support.